Details of the Drug

General Information of Drug (ID: DMBZWQL)

• Drug Name: Clemastine
• Synonyms: Clemastina; Clemastinum; Meclastin; Meclastine; Mecloprodin; Tavegyl; Tavist; CLEMASTINE FUMARATE; HS 592; Clemastina [INN-Spanish]; Clemastine [USAN:BAN]; Clemastinum [INN-Latin]; HS-592; Tavegyl (TN); Tavist (TN); Tavist (*Fumarate*); (+)-(2R)-2-(2-(((R)-p-Chloro-alpha-methyl-alpha-phenylbenzyl)oxy)ethyl)-1-methylpyrrolidine; (+)-(2R)-2-[2-[[(R)-p-Chloro-alpha-methyl-alpha-phenylbenzyl]oxy]ethyl]-1-methylpyrrolidine; (2R)-2-(2-{[(1R)-1-(4-chlorophenyl)-1-phenylethyl]oxy}ethyl)-1-methylpyrrolidine; (2R)-2-[2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine; (2R)-2-{2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl}-1-methylpyrrolidine; 2(R)-[2-[(1R)-(4-Chlorophenyl)-1-phenyl-ethoxy]ethyl-1-methylpyrrolidine; 2-(2-(4-Chlor-alpha-methylbenzhydryloxy)ethyl)-1-methylpyrrolidin

Indication

Disease Entry	ICD 11	Status	REF
Allergic rhinitis	CA08.0	Approved	[1]
Urticaria	EB00-EB05	Approved	[2]
Vasomotor/allergic rhinitis	CA08	Approved	[2]
Pruritus	EC90	Investigative	[2]

• Therapeutic Class: Antiallergic Agents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 343.9
  Logarithm of the Partition Coefficient (xlogp); 5
  Rotatable Bond Count (rotbonds); 6
  Hydrogen Bond Donor Count (hbonddonor); 0
  Hydrogen Bond Acceptor Count (hbondacc); 2
• ADMET Property:
  Absorption: The drug is rapidly absorbed from the gastrointestinal tract []
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
  Elimination: 5% of drug is excreted from urine in the unchanged form [3]
  Metabolism: The drug is metabolized via the liver []
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.38965 micromolar/kg/day [4]
  Water Solubility: The ability of drug to dissolve in water is measured as 2.3 mg/mL [3]
• Chemical Identifiers:
  Formula: C21H26ClNO
  IUPAC Name: (2R)-2-[2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine
  Canonical SMILES: C[C@@](C1=CC=CC=C1)(C2=CC=C(C=C2)Cl)OCC[C@H]3CCCN3C
  InChI: InChI=1S/C21H26ClNO/c1-21(17-7-4-3-5-8-17,18-10-12-19(22)13-11-18)24-16-14-20-9-6-15-23(20)2/h3-5,7-8,10-13,20H,6,9,14-16H2,1-2H3/t20-,21-/m1/s1
  InChIKey: YNNUSGIPVFPVBX-NHCUHLMSSA-N
• Cross-matching ID:
  PubChem CID: 26987
  ChEBI ID: CHEBI:3738
  CAS Number: 15686-51-8
  DrugBank ID: DB00283
  TTD ID: D0C5XC
  VARIDT ID: DR00796
  ACDINA ID: D00135
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Histamine H1 receptor (H1R)	TTTIBOJ	HRH1_HUMAN	Antagonist	[5]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Phosphatidylcholine translocator ABCB4 (ABCB4)	OTE6PY83	MDR3_HUMAN	Gene/Protein Processing	[6]
Potassium voltage-gated channel subfamily H member 2 (KCNH2)	OTZX881H	KCNH2_HUMAN	Gene/Protein Processing	[7]

Molecular Expression Atlas of This Drug

• The Studied Disease: Allergic rhinitis
• ICD Disease Classification: CA08.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Histamine H1 receptor (H1R)	DTT	HRH1	6.74E-01	0.13	0.43

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Clemastine

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Chlorpheniramine	DM5URA2	Moderate	Additive anticholinergic effects by the combination of Clemastine and Chlorpheniramine.	Vasomotor/allergic rhinitis [CA08]	[8]
Triprolidine	DM7SWIA	Moderate	Additive anticholinergic effects by the combination of Clemastine and Triprolidine.	Vasomotor/allergic rhinitis [CA08]	[8]
Methdilazine	DMAUHQX	Moderate	Additive anticholinergic effects by the combination of Clemastine and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[8]
Carbinoxamine	DMCT31R	Moderate	Additive anticholinergic effects by the combination of Clemastine and Carbinoxamine.	Vasomotor/allergic rhinitis [CA08]	[8]
Trimeprazine	DMEMV9D	Moderate	Additive anticholinergic effects by the combination of Clemastine and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[9]
Brompheniramine	DMFOVSD	Moderate	Additive anticholinergic effects by the combination of Clemastine and Brompheniramine.	Vasomotor/allergic rhinitis [CA08]	[8]
Dexbrompheniramine	DMKVWGE	Moderate	Additive anticholinergic effects by the combination of Clemastine and Dexbrompheniramine.	Vasomotor/allergic rhinitis [CA08]	[8]
Cetirizine	DMOMP9U	Moderate	Additive CNS depression effects by the combination of Clemastine and Cetirizine.	Vasomotor/allergic rhinitis [CA08]	[10]
Acrivastine	DMTIGA0	Moderate	Additive anticholinergic effects by the combination of Clemastine and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[8]
Azatadine	DMZ80SB	Moderate	Additive anticholinergic effects by the combination of Clemastine and Azatadine.	Vasomotor/allergic rhinitis [CA08]	[8]

Coadministration of a Drug Treating the Disease Different from Clemastine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Scopolamine	DMOM8AL	Moderate	Additive anticholinergic effects by the combination of Clemastine and Scopolamine.	Addictive disorder [6C50-6C5Z]	[8]
Mepyramine	DMB4SFH	Moderate	Additive anticholinergic effects by the combination of Clemastine and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[9]
Phenyltoloxamine	DMKAEQW	Moderate	Additive anticholinergic effects by the combination of Clemastine and Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[9]
Tripelennamine	DMZBU15	Moderate	Additive anticholinergic effects by the combination of Clemastine and Tripelennamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[8]
Tacrine	DM51FY6	Moderate	Antagonize the effect of Clemastine when combined with Tacrine.	Alzheimer disease [8A20]	[11]
Memantine	DMD9WSC	Moderate	Additive anticholinergic effects by the combination of Clemastine and Memantine.	Alzheimer disease [8A20]	[8]
Galantamine	DMEO794	Moderate	Antagonize the effect of Clemastine when combined with Galantamine.	Alzheimer disease [8A20]	[11]
Rivastigmine	DMG629M	Moderate	Antagonize the effect of Clemastine when combined with Rivastigmine.	Alzheimer disease [8A20]	[11]
Donepezil	DMIYG7Z	Moderate	Antagonize the effect of Clemastine when combined with Donepezil.	Alzheimer disease [8A20]	[11]
Hydroxyzine	DMF8Y74	Moderate	Additive anticholinergic effects by the combination of Clemastine and Hydroxyzine.	Anxiety disorder [6B00-6B0Z]	[8]
Promazine	DMZAL7W	Moderate	Additive anticholinergic effects by the combination of Clemastine and Promazine.	Appearance/behaviour symptom [MB23]	[8]
Desipramine	DMT2FDC	Moderate	Additive anticholinergic effects by the combination of Clemastine and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[8]
Linezolid	DMGFPU2	Moderate	Additive CNS depression effects by the combination of Clemastine and Linezolid.	Bacterial infection [1A00-1C4Z]	[12]
Cariprazine	DMJYDVK	Moderate	Additive anticholinergic effects by the combination of Clemastine and Cariprazine.	Bipolar disorder [6A60]	[8]
Loperamide	DMOJZQ9	Moderate	Additive antimotility effects by the combination of Clemastine and Loperamide.	Bowel habit change [ME05]	[13]
Umeclidinium	DM4E8O9	Moderate	Additive anticholinergic effects by the combination of Clemastine and Umeclidinium.	Chronic obstructive pulmonary disease [CA22]	[14]
Tiotropium	DMFDC0Q	Moderate	Additive anticholinergic effects by the combination of Clemastine and Tiotropium.	Chronic obstructive pulmonary disease [CA22]	[14]
Ipratropium	DMFQ320	Moderate	Additive anticholinergic effects by the combination of Clemastine and Ipratropium.	Chronic obstructive pulmonary disease [CA22]	[14]
Revefenacin	DMMP5SI	Moderate	Additive anticholinergic effects by the combination of Clemastine and Revefenacin.	Chronic obstructive pulmonary disease [CA22]	[14]
Olopatadine	DMKMWQG	Moderate	Additive CNS depression effects by the combination of Clemastine and Olopatadine.	Conjunctiva disorder [9A60]	[15]
Ethanol	DMDRQZU	Moderate	Additive CNS depression effects by the combination of Clemastine and Ethanol.	Cystitis [GC00]	[15]
Trimipramine	DM1SC8M	Moderate	Additive anticholinergic effects by the combination of Clemastine and Trimipramine.	Depression [6A70-6A7Z]	[8]
Cyclobenzaprine	DM1YBRM	Moderate	Additive anticholinergic effects by the combination of Clemastine and Cyclobenzaprine.	Depression [6A70-6A7Z]	[8]
Imipramine	DM2NUH3	Moderate	Additive anticholinergic effects by the combination of Clemastine and Imipramine.	Depression [6A70-6A7Z]	[8]
Nortriptyline	DM4KDYJ	Moderate	Additive anticholinergic effects by the combination of Clemastine and Nortriptyline.	Depression [6A70-6A7Z]	[8]
Isocarboxazid	DMAF1NB	Moderate	Additive CNS depression effects by the combination of Clemastine and Isocarboxazid.	Depression [6A70-6A7Z]	[12]
Tranylcypromine	DMGB5RE	Moderate	Additive CNS depression effects by the combination of Clemastine and Tranylcypromine.	Depression [6A70-6A7Z]	[12]
OPC-34712	DMHG57U	Moderate	Additive anticholinergic effects by the combination of Clemastine and OPC-34712.	Depression [6A70-6A7Z]	[8]
Phenelzine	DMHIDUE	Moderate	Additive CNS depression effects by the combination of Clemastine and Phenelzine.	Depression [6A70-6A7Z]	[12]
Clomipramine	DMINRKW	Moderate	Additive anticholinergic effects by the combination of Clemastine and Clomipramine.	Depression [6A70-6A7Z]	[8]
Amitriptyline	DMK7F9S	Moderate	Additive anticholinergic effects by the combination of Clemastine and Amitriptyline.	Depression [6A70-6A7Z]	[8]
Amoxapine	DMKITQE	Moderate	Additive anticholinergic effects by the combination of Clemastine and Amoxapine.	Depression [6A70-6A7Z]	[8]
Protriptyline	DMNHTZI	Moderate	Additive anticholinergic effects by the combination of Clemastine and Protriptyline.	Depression [6A70-6A7Z]	[8]
Doxepin	DMPI98T	Moderate	Additive anticholinergic effects by the combination of Clemastine and Doxepin.	Depression [6A70-6A7Z]	[8]
Maprotiline	DMPWB7T	Moderate	Additive anticholinergic effects by the combination of Clemastine and Maprotiline.	Depression [6A70-6A7Z]	[8]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Clemastine and Esketamine.	Depression [6A70-6A7Z]	[16]
Hyoscyamine	DM804UR	Moderate	Additive anticholinergic effects by the combination of Clemastine and Hyoscyamine.	Digestive system disease [DE2Z]	[8]
Mepenzolate	DM8YU2F	Moderate	Additive anticholinergic effects by the combination of Clemastine and Mepenzolate.	Digestive system disease [DE2Z]	[8]
Oxybutynine	DMJPBAX	Moderate	Additive anticholinergic effects by the combination of Clemastine and Oxybutynine.	Discovery agent [N.A.]	[8]
Meclizine	DMS7T13	Moderate	Additive anticholinergic effects by the combination of Clemastine and Meclizine.	Dizziness and giddiness [MB48]	[8]
Trihexyphenidyl	DMB19L8	Moderate	Additive anticholinergic effects by the combination of Clemastine and Trihexyphenidyl.	Dystonic disorder [8A02]	[8]
Zonisamide	DM0DTF7	Major	Additive CNS depression effects by the combination of Clemastine and Zonisamide.	Epilepsy/seizure [8A61-8A6Z]	[17]
Diphenhydramine	DMKQTBA	Moderate	Additive anticholinergic effects by the combination of Clemastine and Diphenhydramine.	Episodic vestibular syndrome [AB31]	[8]
Timolol	DM3NXRU	Moderate	Decreased metabolism of Clemastine caused by Timolol mediated inhibition of CYP450 enzyme.	Essential hypertension [BA00]	[18]
Solifenacin	DMG592Q	Moderate	Additive anticholinergic effects by the combination of Clemastine and Solifenacin.	Functional bladder disorder [GC50]	[8]
Tolterodine	DMSHPW8	Moderate	Additive anticholinergic effects by the combination of Clemastine and Tolterodine.	Functional bladder disorder [GC50]	[8]
Propantheline	DM2EN6G	Moderate	Additive anticholinergic effects by the combination of Clemastine and Propantheline.	Gastric ulcer [DA60]	[8]
Isoflurophate	DMBSK7X	Moderate	Antagonize the effect of Clemastine when combined with Isoflurophate.	Glaucoma [9C61]	[19]
Brimonidine	DMQLT4N	Moderate	Additive CNS depression effects by the combination of Clemastine and Brimonidine.	Glaucoma [9C61]	[20]
Pilocarpine	DMV9ADG	Moderate	Antagonize the effect of Clemastine when combined with Pilocarpine.	Glaucoma [9C61]	[19]
Procarbazine	DMIK367	Moderate	Additive CNS depression effects by the combination of Clemastine and Procarbazine.	Hodgkin lymphoma [2B30]	[12]
Potassium chloride	DMMTAJC	Major	Increased risk of GI mucosal injury/bleeding risk by the combination of Clemastine and Potassium chloride.	Hypo-kalaemia [5C77]	[21]
Belladonna	DM2RBWK	Moderate	Additive anticholinergic effects by the combination of Clemastine and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[8]
Amantadine	DMS3YE9	Moderate	Additive anticholinergic effects by the combination of Clemastine and Amantadine.	Influenza [1E30-1E32]	[22]
ITI-007	DMUQ1DO	Moderate	Additive anticholinergic effects by the combination of Clemastine and ITI-007.	Insomnia [7A00-7A0Z]	[8]
Clidinium	DMUMQZ0	Moderate	Additive anticholinergic effects by the combination of Clemastine and Clidinium.	Irritable bowel syndrome [DD91]	[8]
Dicyclomine	DMZSDGX	Moderate	Additive anticholinergic effects by the combination of Clemastine and Dicyclomine.	Irritable bowel syndrome [DD91]	[8]
Physostigmine	DM2N0TO	Moderate	Antagonize the effect of Clemastine when combined with Physostigmine.	Lips/oral mucosa miscellaneous disorder [DA02]	[11]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Clemastine and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[23]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Clemastine and Lasmiditan.	Migraine [8A80]	[24]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Clemastine and Flibanserin.	Mood disorder [6A60-6E23]	[25]
Doxylamine	DMKOXFE	Moderate	Additive anticholinergic effects by the combination of Clemastine and Doxylamine.	Morning sickness disorder [SC00]	[8]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Clemastine and Thalidomide.	Multiple myeloma [2A83]	[26]
Ozanimod	DMT6AM2	Moderate	Additive CNS depression effects by the combination of Clemastine and Ozanimod.	Multiple sclerosis [8A40]	[12]
Dimenhydrinate	DM264B3	Moderate	Additive anticholinergic effects by the combination of Clemastine and Dimenhydrinate.	Nausea/vomiting [MD90]	[8]
Prochlorperazine	DM53SRA	Moderate	Additive anticholinergic effects by the combination of Clemastine and Prochlorperazine.	Nausea/vomiting [MD90]	[8]
Promethazine	DM6I5GR	Moderate	Additive anticholinergic effects by the combination of Clemastine and Promethazine.	Nausea/vomiting [MD90]	[8]
Cyclizine	DM9G7BS	Moderate	Additive anticholinergic effects by the combination of Clemastine and Cyclizine.	Nausea/vomiting [MD90]	[8]
Thiethylperazine	DMU3IET	Moderate	Additive anticholinergic effects by the combination of Clemastine and Thiethylperazine.	Nausea/vomiting [MD90]	[8]
Apraclonidine	DMO4PVE	Moderate	Additive CNS depression effects by the combination of Clemastine and Apraclonidine.	Optic nerve disorder [9C40]	[20]
Dextropropoxyphene	DM23HCX	Major	Additive CNS depression effects by the combination of Clemastine and Dextropropoxyphene.	Pain [MG30-MG3Z]	[27]
Flavoxate	DMKV4NL	Moderate	Additive anticholinergic effects by the combination of Clemastine and Flavoxate.	Pain [MG30-MG3Z]	[8]
Biperiden	DME78OA	Moderate	Additive anticholinergic effects by the combination of Clemastine and Biperiden.	Parkinsonism [8A00]	[8]
Procyclidine	DMHFJDT	Moderate	Additive anticholinergic effects by the combination of Clemastine and Procyclidine.	Parkinsonism [8A00]	[8]
Orphenadrine	DMW542E	Moderate	Additive anticholinergic effects by the combination of Clemastine and Orphenadrine.	Parkinsonism [8A00]	[8]
Methylscopolamine	DM5VWOB	Moderate	Additive anticholinergic effects by the combination of Clemastine and Methylscopolamine.	Peptic ulcer [DA61]	[8]
Levomepromazine	DMIKFEL	Moderate	Additive anticholinergic effects by the combination of Clemastine and Levomepromazine.	Psychotic disorder [6A20-6A25]	[8]
Fluphenazine	DMIT8LX	Moderate	Additive anticholinergic effects by the combination of Clemastine and Fluphenazine.	Psychotic disorder [6A20-6A25]	[8]
Triflupromazine	DMKFQJP	Moderate	Additive anticholinergic effects by the combination of Clemastine and Triflupromazine.	Psychotic disorder [6A20-6A25]	[8]
Cyproheptadine	DM92AH3	Moderate	Additive anticholinergic effects by the combination of Clemastine and Cyproheptadine.	Rheumatoid arthritis [FA20]	[8]
Quetiapine	DM1N62C	Moderate	Additive anticholinergic effects by the combination of Clemastine and Quetiapine.	Schizophrenia [6A20]	[8]
Mesoridazine	DM2ZGAN	Moderate	Additive anticholinergic effects by the combination of Clemastine and Mesoridazine.	Schizophrenia [6A20]	[8]
Thioridazine	DM35M8J	Moderate	Additive anticholinergic effects by the combination of Clemastine and Thioridazine.	Schizophrenia [6A20]	[8]
Aripiprazole	DM3NUMH	Moderate	Additive anticholinergic effects by the combination of Clemastine and Aripiprazole.	Schizophrenia [6A20]	[8]
Iloperidone	DM6AUFY	Moderate	Additive anticholinergic effects by the combination of Clemastine and Iloperidone.	Schizophrenia [6A20]	[8]
Paliperidone	DM7NPJS	Moderate	Additive anticholinergic effects by the combination of Clemastine and Paliperidone.	Schizophrenia [6A20]	[8]
Loxapine	DM8AI9U	Moderate	Additive anticholinergic effects by the combination of Clemastine and Loxapine.	Schizophrenia [6A20]	[8]
Haloperidol	DM96SE0	Moderate	Additive anticholinergic effects by the combination of Clemastine and Haloperidol.	Schizophrenia [6A20]	[8]
Perphenazine	DMA4MRX	Moderate	Additive anticholinergic effects by the combination of Clemastine and Perphenazine.	Schizophrenia [6A20]	[8]
Molindone	DMAH70G	Moderate	Additive anticholinergic effects by the combination of Clemastine and Molindone.	Schizophrenia [6A20]	[8]
Chlorpromazine	DMBGZI3	Moderate	Additive anticholinergic effects by the combination of Clemastine and Chlorpromazine.	Schizophrenia [6A20]	[8]
Thiothixene	DMDINC4	Moderate	Additive anticholinergic effects by the combination of Clemastine and Thiothixene.	Schizophrenia [6A20]	[8]
Clozapine	DMFC71L	Moderate	Additive anticholinergic effects by the combination of Clemastine and Clozapine.	Schizophrenia [6A20]	[8]
Trifluoperazine	DMKBYWI	Moderate	Additive anticholinergic effects by the combination of Clemastine and Trifluoperazine.	Schizophrenia [6A20]	[8]
Risperidone	DMN6DXL	Moderate	Additive anticholinergic effects by the combination of Clemastine and Risperidone.	Schizophrenia [6A20]	[8]
Olanzapine	DMPFN6Y	Moderate	Additive anticholinergic effects by the combination of Clemastine and Olanzapine.	Schizophrenia [6A20]	[8]
Asenapine	DMSQZE2	Moderate	Additive anticholinergic effects by the combination of Clemastine and Asenapine.	Schizophrenia [6A20]	[8]
Pimozide	DMW83TP	Moderate	Additive anticholinergic effects by the combination of Clemastine and Pimozide.	Schizophrenia [6A20]	[8]
Atropine	DMEN6X7	Moderate	Additive anticholinergic effects by the combination of Clemastine and Atropine.	Unspecific substance harmful effect [NE6Z]	[8]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Clemastine 1.34 mg tablet	1.34 mg	Oral Tablet	Oral
Clemastine 1.34 mg tablet	1.34 mg	12 HR Extended Release Oral Tablet	Oral
Clemastine 2.68 mg tablet	2.68 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6063).
• [2] Clemastine FDA Label
• [3] BDDCS applied to over 900 drugs
• [4] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [5] Histamine upregulates keratinocyte MMP-9 production via the histamine H1 receptor. J Invest Dermatol. 2008 Dec;128(12):2783-91.
• [6] Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals. Chem Res Toxicol. 2017 May 15;30(5):1219-1229. doi: 10.1021/acs.chemrestox.7b00048. Epub 2017 May 4.
• [7] Why are most phospholipidosis inducers also hERG blockers?. Arch Toxicol. 2017 Dec;91(12):3885-3895. doi: 10.1007/s00204-017-1995-9. Epub 2017 May 27.
• [8] Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
• [9] Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
• [10] Product Information. Zyrtec (cetirizine). Pfizer US Pharmaceuticals, New York, NY.
• [11] Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
• [12] Canadian Pharmacists Association.
• [13] Eronen M, Putkonen H, Hallikainen T, Vartiainen H "Lethal gastroenteritis associated with clozapine and loperamide." Am J Psychiatry 160 (2003): 2242-2243. [PMID: 14638602]
• [14] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
• [15] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
• [16] Cerner Multum, Inc. "Australian Product Information.".
• [17] Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
• [18] Edeki TI, He HB, Wood AJJ "Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops: potential for oral-ophthalmic drug interaction." JAMA 274 (1995): 1611-3. [PMID: 7474246]
• [19] Multum Information Services, Inc. Expert Review Panel.
• [20] Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
• [21] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206. [PMID: 1148734]
• [22] Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975): 212-5. [PMID: 123540]
• [23] Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
• [24] Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
• [25] Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
• [26] Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
• [27] Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67. [PMID: 6998251]